

NOTICE FROM EXECUTIVE OFFICER

December 1, 2008

Announcement of Changes to the Formulary respecting Enalapril Maleate

This notice is to inform all interested parties that the Call for Application for Enalapril Maleate (Call for Applications No. 2008-025) has been successfully completed. I am pleased to advise that Merck Frosst Canada Ltd. is the successful applicant for this Call. As a result, we will be making changes to the drug product listings for Enalapril Maleate.

I am writing to notify you that I intend to make changes to the Ontario Drug Benefit/Comparative Drug Index Formulary (Formulary) **effective January 8, 2009** respecting the drug products for Enalapril Maleate.

The following drug products will be the only drug products listed on the Formulary that will be available as benefits under the Ontario Drug Benefit (ODB) Program as of the above effective date for Enalapril Maleate:

- Vasotec 2.5mg tablets
- Vasotec 5 mg tablets
- Vasotec 10mg tablets
- Vasotec 20mg tablets

Please note that claims will only be allowed for the above-named products. The current interchangeable products will continue to be listed as “Not a Benefit” for interchangeability purposes for non-ODB recipients.

The decision to make these changes has been made after considering the public interest, including the ability of the government of Ontario to achieve cost savings as well as other factors, and is made on the authority of the *Ontario Drug Benefit Act*.

Helen Stevenson
Executive Officer
Ontario Public Drug Programs